{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:28:20Z","timestamp":1792758500873,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary biliary cholangitis (PBC) is frequently associated with autoimmune disease. Although PBC complicated with CREST syndrome (PBC-CREST) has been reported, the long-term outcomes of the affected patients have not been fully investigated. Herein, the long-term outcomes of PBC-CREST were evaluated. Next, the GLOBE and UK-PBC scores were validated and compared between the PBC alone and PBC-CREST groups. A total of 302 patients who were diagnosed with PBC between December 1990 and August 2021 at Fukushima Medical University Hospital were included. The liver transplantation (LT)-free survival rates were compared between patients with PBC alone (n\u2009=\u2009245) and those with PBC-CREST (n\u2009=\u200957). Moreover, 173 patients, excluding those with liver-related death\/LT within 1\u00a0year after ursodeoxycholic acid administration, were divided into two subgroups (PBC alone (n\u2009=\u2009147) and PBC-CREST (n\u2009=\u200926)), and the GLOBE and UK-PBC scores were compared between the subgroups. The survival rates without LT (3\/5\/10\u00a0years) were 92\/87\/80% for the PBC-alone group and 98\/96\/96% for the PBC-CREST group, with a significantly better prognosis in the PBC-CREST group (log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.0172). Multivariate analysis revealed that the presence of CREST syndrome is an independent protective factor for the presence of cirrhosis. The predicted 5\/10\/15-year risks of liver-related death or LT based on the UK-PBC score were significantly lower in the PBC-CREST group (2.4\/7.6\/13.2%) than in the PBC-alone group (4.8\/11.8\/18.8%) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The predicted 3\/5-year LT-free survival rates based on the GLOBE score were significantly higher in the PBC-CREST group (93\/88%) than in the PBC-alone group (88\/81%) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Patients with PBC-CREST may have better long-term outcomes than those with PBC alone.<\/jats:p>","DOI":"10.1038\/s41598-024-64976-8","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:04:08Z","timestamp":1718780648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome"],"prefix":"10.1038","volume":"14","author":[{"given":"Kazumichi","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"64976_CR1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","volume":"377","author":"C Selmi","year":"2011","unstructured":"Selmi, C., Bowlus, C. L., Gershwin, M. E. & Coppel, R. L. Primary biliary cirrhosis. Lancet 377, 1600\u20131609 (2011).","journal-title":"Lancet"},{"key":"64976_CR2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40744-017-0074-2","volume":"4","author":"C Selmi","year":"2017","unstructured":"Selmi, C. & Gershwin, M. E. Chronic autoimmune Epithelitis in Sj\u00f6gren\u2019s syndrome and primary biliary cholangitis: A comprehensive review. Rheumatol. Ther. 4, 263\u2013279 (2017).","journal-title":"Rheumatol. Ther."},{"key":"64976_CR3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5009\/gnl16365","volume":"11","author":"SL Chalifoux","year":"2017","unstructured":"Chalifoux, S. L., Konyn, P. G., Choi, G. & Saab, S. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver. 11, 771\u2013780 (2017).","journal-title":"Gut Liver."},{"key":"64976_CR4","first-page":"5557814","volume":"2021","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Clinical characteristics and prognosis of concomitant primary biliary cholangitis and autoimmune diseases: A retrospective study. Can. J. Gastroenterol. Hepatol. 2021, 5557814 (2021).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"64976_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2397198318802763","volume":"4","author":"G Lepri","year":"2019","unstructured":"Lepri, G. et al. Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. J. Scleroderma Relat. Disord. 4, 111\u2013117 (2019).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"64976_CR6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/hepr.12285","volume":"44","author":"H Ohira","year":"2014","unstructured":"Ohira, H. & Watanabe, H. Pathophysiology and recent findings of primary biliary cirrhosis complicated by systemic sclerosis. Hepatol. Res. 44, 377\u2013383 (2014).","journal-title":"Hepatol. Res."},{"key":"64976_CR7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/bmj.3.5717.258","volume":"3","author":"IM Murray-Lyon","year":"1970","unstructured":"Murray-Lyon, I. M., Thompson, R. P., Ansell, I. D. & Williams, R. Scleroderma and primary biliary cirrhosis. Br. Med. J. 3, 258\u2013259 (1970).","journal-title":"Br. Med. J."},{"key":"64976_CR8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0002-9343(71)90218-X","volume":"50","author":"TB Reynolds","year":"1971","unstructured":"Reynolds, T. B. et al. Primary biliary cirrhosis with scleroderma, Raynaud\u2019s phenomenon and telangiectasia. New Syndrome. Am. J. Med. 50, 302\u2013312 (1971).","journal-title":"Am. J. Med."},{"key":"64976_CR9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/qjmed\/hch078","volume":"97","author":"FE Watt","year":"2004","unstructured":"Watt, F. E., James, O. F. & Jones, D. E. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study. QJM 97, 397\u2013406 (2004).","journal-title":"QJM"},{"key":"64976_CR10","first-page":"75","volume":"62","author":"FC Powell","year":"1987","unstructured":"Powell, F. C., Schroeter, A. L. & Dickson, E. R. Primary biliary cirrhosis and the CREST syndrome: A report of 22 cases. QJ Med. 62, 75\u201382 (1987).","journal-title":"QJ Med."},{"key":"64976_CR11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.1780310310","volume":"31","author":"DR Fregeau","year":"1988","unstructured":"Fregeau, D. R. et al. Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 31, 386\u201392 (1988).","journal-title":"Arthritis Rheum"},{"key":"64976_CR12","doi-asserted-by":"crossref","first-page":"102114","DOI":"10.1016\/j.clinre.2023.102114","volume":"47","author":"KV Malkani","year":"2023","unstructured":"Malkani, K. V., Jesudian, A. B., Luo, J. J. & Schonfeld, E. A. Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome. Clin. Res. Hepatol. Gastroenterol. 47, 102114 (2023).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"64976_CR13","first-page":"e11986","volume":"12","author":"SI Khan","year":"2020","unstructured":"Khan, S. I. et al. Primary biliary cholangitis and CREST syndrome: A rare, overlapping presentation with a review of the literature. Cureus 12, e11986 (2020).","journal-title":"Cureus"},{"key":"64976_CR14","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.amjmed.2017.05.019","volume":"130","author":"A Kiyani","year":"2017","unstructured":"Kiyani, A. & Ursu, S. Coexistent primary biliary cholangitis with CREST syndrome (Reynolds syndrome). Am. J. Med. 130, e501\u2013e502 (2017).","journal-title":"Am. J. Med."},{"key":"64976_CR15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjms.2022.12.005","volume":"365","author":"B Collins","year":"2023","unstructured":"Collins, B., Dillon, D. & Silver, R. M. PACK syndrome: A case series and review. Am. J. Med. Sci. 365, 321\u2013328 (2023).","journal-title":"Am. J. Med. Sci."},{"key":"64976_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1386-6346(01)00138-3","volume":"22","author":"J Tojo","year":"2002","unstructured":"Tojo, J. et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol. Res. 22, 187\u2013195 (2002).","journal-title":"Hepatol. Res."},{"key":"64976_CR17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0178-x","volume":"26","author":"T Nakamura","year":"2007","unstructured":"Nakamura, T. et al. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sj\u00f6gren\u2019s syndrome and thyroid dysfunction. Clin. Rheumatol. 26, 596\u2013600 (2007).","journal-title":"Clin. Rheumatol."},{"key":"64976_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology 50, 291\u2013308 (2009).","journal-title":"Hepatology"},{"key":"64976_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","year":"2017","unstructured":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. J. Hepatol. 67, 145\u2013172 (2017).","journal-title":"J. Hepatol."},{"issue":"1","key":"64976_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hepr.12270","volume":"44","author":"Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis","year":"2014","unstructured":"Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol. Res. 44(1), 71\u201390 (2014).","journal-title":"Hepatol. Res."},{"key":"64976_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","volume":"16","author":"H You","year":"2022","unstructured":"You, H. et al. APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis. Hepatol. Int. 16, 1\u201323 (2022).","journal-title":"Hepatol. Int."},{"key":"64976_CR22","first-page":"15","volume":"85","author":"Y Matsuzaki","year":"1990","unstructured":"Matsuzaki, Y. et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 85, 15\u201323 (1990).","journal-title":"Am. J. Gastroenterol."},{"key":"64976_CR23","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon, R. E., Balkau, B., Eschwege, E. & Poupon, R. A multicentre, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324, 1548\u20131554 (1991).","journal-title":"N. Engl. J. Med."},{"key":"64976_CR24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s, A. et al. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130, 715\u2013720 (2006).","journal-title":"Gastroenterology"},{"key":"64976_CR25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48, 871\u2013877 (2008).","journal-title":"Hepatology"},{"key":"64976_CR26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper, E. M. et al. . Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136, 1281\u20137 (2009).","journal-title":"Gastroenterology"},{"key":"64976_CR27","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi, T. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am. J. Gastroenterol. 105, 2186\u20132194 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"64976_CR28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot, C., Chazouill\u00e8res, O. & Poupon, R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J. Hepatol. 55, 1361\u20131367 (2011).","journal-title":"J. Hepatol."},{"key":"64976_CR29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers, W. J. et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149, 1804\u20131812 (2015).","journal-title":"Gastroenterology"},{"key":"64976_CR30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","volume":"63","author":"M Carbone","year":"2016","unstructured":"Carbone, M. et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 63, 930\u2013950 (2016).","journal-title":"Hepatology"},{"key":"64976_CR31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","volume":"2","author":"M Carbone","year":"2018","unstructured":"Carbone, M. et al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Hepatol. Commun. 2, 683\u2013692 (2018).","journal-title":"Hepatol. Commun."},{"key":"64976_CR32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep4.1186","volume":"2","author":"AC Cheung","year":"2018","unstructured":"Cheung, A. C. et al. External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Hepatol. Commun. 2, 676\u2013682 (2018).","journal-title":"Hepatol. Commun."},{"key":"64976_CR33","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda, A. et al. Improved GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology 70, 2035\u20132046 (2019).","journal-title":"Hepatology"},{"key":"64976_CR34","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/hep4.2103","volume":"6","author":"D Ding","year":"2022","unstructured":"Ding, D. et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol. Commun. 6, 3487\u20133495 (2022).","journal-title":"Hepatol. Commun."},{"key":"64976_CR35","first-page":"1135","volume":"43","author":"T Remmel","year":"1996","unstructured":"Remmel, T. et al. Clinical significance of different antinuclear antibodies patterns during primary biliary cirrhosis. Hepatogastroenterology 43, 1135\u20131140 (1996).","journal-title":"Hepatogastroenterology"},{"key":"64976_CR36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","volume":"55","author":"C Rigamonti","year":"2006","unstructured":"Rigamonti, C. et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55, 388\u2013394 (2006).","journal-title":"Gut"},{"key":"64976_CR37","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3899\/jrheum.090340","volume":"36","author":"S Assassi","year":"2009","unstructured":"Assassi, S. et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J. Rheumatol. 36, 2250\u20132256 (2009).","journal-title":"J. Rheumatol."},{"key":"64976_CR38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/s10165-012-0607-z","volume":"22","author":"S Imura-Kumada","year":"2012","unstructured":"Imura-Kumada, S. et al. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod. Rheumatol. 22, 892\u2013898 (2012).","journal-title":"Mod. Rheumatol."},{"key":"64976_CR39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura, M. et al. Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45, 118\u2013127 (2007).","journal-title":"Hepatology"},{"key":"64976_CR40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","volume":"45","author":"F Yang","year":"2017","unstructured":"Yang, F. et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210. Aliment Pharmacol. Ther. 45, 733\u2013743 (2017).","journal-title":"Aliment Pharmacol. Ther."},{"key":"64976_CR41","first-page":"1257","volume":"60","author":"P Scheuer","year":"1967","unstructured":"Scheuer, P. Primary biliary cirrhosis. Proc. R. Soc. Med. 60, 1257\u20131260 (1967).","journal-title":"Proc. R. Soc. Med."},{"key":"64976_CR42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0016-5107(99)70447-5","volume":"49","author":"AJ Cameron","year":"1999","unstructured":"Cameron, A. J., Malcolm, A., Prather, C. M. & Phillips, S. F. Videoendoscopic diagnosis of oesophageal motility disorders. Gastrointest. Endosc. 49, 62\u201369 (1999).","journal-title":"Gastrointest. Endosc."},{"key":"64976_CR43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41584-022-00900-6","volume":"19","author":"ZH McMahan","year":"2023","unstructured":"McMahan, Z. H. et al. Systemic sclerosis gastrointestinal dysmotility: Risk factors, pathophysiology, diagnosis and management. Nat. Rev. Rheumatol. 19, 166\u2013181 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"64976_CR44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/diagnostics13040695","volume":"13","author":"S Kuribayashi","year":"2023","unstructured":"Kuribayashi, S., Hosaka, H. & Uraoka, T. Usefulness of endoscopy for the detection and diagnosis of primary oesophageal motility disorders and diseases relating to abnormal oesophageal motility. Diagnostics (Basel) 13, 695 (2023).","journal-title":"Diagnostics (Basel)"},{"key":"64976_CR45","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2169\/internalmedicine.31.1348","volume":"31","author":"I Shoji","year":"1992","unstructured":"Shoji, I., Takagi, T. & Kasukawa, R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern. Med. 31, 1348\u20131355 (1992).","journal-title":"Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64976-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:16:54Z","timestamp":1720523814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64976-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["64976"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-64976-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14124"}}